Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

Callio Therapeutics Names Zachary Hornby As CEO To Advance Dual-Payload Cancer ...

11 September 2026 · By · Wire by Fusion42

Published

11 September 2026

Topic

opportunities

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at pulse2.com →

◆ Verified

Fusion42 · 11 September 2026 · Fusion42 review

Callio Therapeutics named Zachary Hornby as CEO to advance its dual-payload antibody-drug conjugates for cancer treatment, progressing CLIO-8221 in Phase 1/2 trials in multiple countries including the US, Australia, and China. Hornby’s leadership experience includes managing clinical development, financing, and a major $2 billion acquisition by Roche.

This Wire brief sits within Fusion42's coverage of Biotech.

◆ ◆ The Wire takeaway

Biotech founders in oncology drug development must consider how dual-payload ADCs could shift competitive advantage; Hornby’s proven fundraising and exit expertise could open strategic partnership doors in your sector.

◆ Coverage

1 source · 11 Sep 2026

◆ Related on Wire

◆ Topics

Biotechcancerbiotechdrug-developmentclinical-trialsleadership